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PEMFOSFORILAN DAN PENGAWALATURAN KOLINA KINASE BETA 
MANUSIA OLEH PROTEIN KINASE A 
 
ABSTRAK 
Kolina kinase (CK) adalah enzim pertama yang terlibat dalam laluan CDP-kolina 
untuk proses biosintesis fosfatidilkolina yang merupakan komponen utama fosfolipid 
membran. CK terdiri daripada tiga isoform iaitu CKα1, CKα2 dan CKβ. 
Pengawalaturan enzim ini adalah penting dari segi fisiologi. Perubahan metabolik 
CKα telah dikaitkan dengan pembentukan tumor, manakala mutasi atau pemadaman 
gen chkβ boleh menyebabkan distrofi otot. Dalam kajian antikanser, perencatan 
aktiviti CK telah diteroka sebagai strategi terapeutik yang berpotensi. 
Pengubahsuaian pasca translasi merupakan salah satu mekanisme untuk mengawal 
fungsi CK. Semakin banyak bukti menunjukkan bahawa fungsi CK dalam yis dan 
CKα dalam manusia dikawalatur oleh pemfosforilan. Namum begitu, pemfosforilan 
CKβ tidak pernah dilaporkan. Dalam kajian ini, protein kinase A (PKA) telah 
dikenalpasti sebagai protein kinase yang bertanggungjawab dalam pemfosforilan 
CKβ melalui analisis in-gel kinase. Pemfosforilan oleh PKA telah disahkan melalui 
teknik analisis perencat PKA dan blot Western. Analisis in vitro dengan 
menggunakan PKA komersil juga membuktikan bahawa CKβ merupakan substrat 
untuk pemfosforilan PKA. Pemfosforilan ini berlaku pada terminal-N CKβ iaitu asid 
amino serine 39 dan 40. Pemfosforilan CKβ telah dilihat dalam sel embrio ginjal 
manusia (HEK293) dan sel karsinoma hati manusia (HepG2). Rawatan forskolin dan 
3-isobutil-1-metilxantin meningkatkan tahap pemfosforilan pada CKβ manakala 
kesan tersebut direncatkan oleh perencat PKA (H-89). Tahap pemfosforilan CKβ 
juga ditingkatkan oleh rawatan faktor pertumbuhan epidermis. Seterusnya, kesan 
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pemfosforilan terhadap ciri-ciri biokimia CKβ juga dikaji. Pemfosforilan PKA telah 
meningkatkan aktiviti pemangkinan CKβ terhadap kolina, etanolamina dan ATP. 
Nilai Vmax untuk kolina, etanolamina dan ATP telah masing-masing meningkat 
sebanyak 47.1%, 81.8% dan 50.8%. Pemfosforilan PKA juga telah meningkatkan 
tarikan CKβ terhadap substrat kolina dan ATP, tetapi pemfosforilan menurunkan 
tarikan CKβ terhadap substrat etanolamina. Kecekapan pemangkinan CKβ untuk 
kolina dan ATP telah meningkat sebanyak 121.0% dan 97.5% masing-masing. Kesan 
pemfosforilan PKA terhadap ciri-ciri biokimia CKβ telah ditiru oleh mutasi berganda 
pada serine yang difosforilasi dengan penukaran kepada aspartat. Pemfosforilan juga 
meningkatkan sensitiviti CKβ terhadap perencatan oleh hemicholinium-3 (HC-3) 
yang merupakan perencat CK yang kuat. Nilai IC50 CKβ terfosforilasi (50 μM) 
adalah 29 kali ganda lebih rendah daripada enzim tidak terfosforilasi (1.45 mM). 
Selain itu, pemfosforilan juga mengurangkan kestabilan CKβ terhadap penyahaslian 
urea. Sebaliknya, pemfosforilan tidak menjejaskan pH optima, lokasi subsel dan 
status oligomer CKβ. Kajian ini melaporkan fosforilasi dan pengawalaturan CKβ 
oleh PKA untuk kali pertama. Pengetahuan ini memberikan pandangan baru terhadap 
pengawalaturan intrasel ciri-ciri pemangkinan CKβ yang mungkin merupakan 
mekanisme penting untuk mengawal metabolisme lipid and pertumbuhan sel.  
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PHOSPHORYLATION AND REGULATION OF  
HUMAN CHOLINE KINASE BETA BY PROTEIN KINASE A 
 
ABSTRACT 
 
Choline kinase (CK) is the first enzyme involved in CDP-choline pathway for the 
biosynthesis of phosphatidylcholine, the major component of membrane 
phospholipid. CK exists as three isoforms, which are CKα1, CKα2 and CKβ. The 
regulation of these enzymes is physiologically important. Metabolic alterations of 
CKα are associated with tumorigenesis, while mutation or deletion of chkβ gene 
leads to the development of muscular dystrophy. In anticancer research, inhibition of 
CK activity has been explored as a potential therapeutic strategy. Post-translational 
modification is one of the mechanisms to regulate the function of CK. Growing 
evidences support that yeast and human CKα are regulated by phosphorylation but 
the phosphorylation of CKβ has never been reported. In this study, protein kinase A 
(PKA) was identified as the protein kinase responsible for the phosphorylation of 
CKβ by in-gel kinase assay. PKA phosphorylation was confirmed with specific PKA 
inhibitor and Western blotting. In vitro assay with commercial PKA further 
supported CKβ as the substrate for PKA phosphorylation. The phosphorylation 
occurred at serine 39 and 40 residues in the N-terminal region of CKβ. 
Phosphorylation of CKβ was observed in human embryonic kidney cells (HEK293) 
and liver hepatocellular carcinoma cells (HepG2). Forskolin and 3-isobutyl-1-
methylxanthine treatment increased the phosphorylation level of CKβ, while the 
phosphorylation was inhibited by PKA inhibitor (H-89). The phosphorylation level 
of CKβ was also increased by epidermal growth factor. The effects of PKA 
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phosphorylation on the biochemical properties of CKβ were subsequently examined. 
PKA phosphorylation increased the catalytic activities of CKβ with choline, 
ethanolamine and ATP as substrates. The Vmax values for choline, ethanolamine and 
ATP were increased by 47.1%, 81.8% and 50.8%, respectively. PKA 
phosphorylation improved the affinity of CKβ for choline and ATP, but decreased 
the affinity of CKβ for ethanolamine. Consequently, the catalytic efficiencies of CKβ 
for choline and ATP were increased by 121.0% and 97.5%, respectively. The same 
effects of PKA phosphorylation on the biochemical properties of CKβ were 
mimicked by double mutation of the phosphorylated serines to aspartates. PKA 
phosphorylation also dramatically increased the sensitivity of CKβ to 
hemicholinium-3 (HC-3), a potent inhibitor of CK. The IC50 value for 
phosphorylated  CKβ (50 μM) was 29 times lower than the unphosphorylated 
enzyme (1.45 mM). In addition, PKA phosphorylation also decreased the stability of 
CKβ protein against urea denaturation. On the contrary, phosphorylation did not 
affect the optimum pH, subcellular location and oligomeric state of CKβ. This study 
reports the phosphorylation and regulation of CKβ by PKA for the first time. The 
knowledge provides new insight into the intracellular regulation of CKβ catalytic 
properties by phosphorylation that might be an important mechanism to modulate 
lipid metabolism and cell growth.  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Kennedy pathway 
Kennedy pathway (Figure 1.1) which consists of CDP-choline and CDP-
ethanolamine pathways decribes the de novo biosynthesis of major phospholipid 
components of the cell (Kennedy and Weiss, 1956). In CDP-choline pathway, CK 
catalyzes the phosphorylation of choline to phosphocholine (PCho) using adenosine 
triphosphate (ATP) and magnesium (Mg
2+
) as substrate and cofactor, respectively 
(Ishidate, 1997). The second enzyme in this pathway is CTP-phosphocholine 
cytidylyltransferase (CCT) which converts the PCho into CDP-choline. CDP-
choline phosphoryltransferase (CPT) catalyzes the final condensation of CDP-
choline to form PC (Kent, 1990, Gibellini and Smith, 2010). For CDP-ethanolamine 
pathway, ethanolamine is converted into phosphoethanolamine (PEtn) by EK and 
followed the similar steps as the CDP-choline pathway (Gibellini and Smith, 2010). 
In liver, the end product of CDP-ethanolamine pathway, the PE, can be converted 
into PC by phosphoethanolamine methyltransferase (PEMT) (Li and Vance, 2008).  
 
1.2 Choline kinase 
Human CK is composed of CKα1, CKα2 and CKβ isoforms. CKα and CKβ are 
encoded by two separate genes, chkα (NCBI Gene ID: 1119) and chkβ (NCBI Gene 
ID: 1120) in chromosomes 11q13.2 and 23q13.33, respectively. CKα undergoes 
alternative splicing to form CKα1 (NCBI reference sequence: NP_005189) and 
CKα2 (NCBI reference sequence: NP_001268) with the calculated molecular size of  
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                      CK                           CCT                                       CPT 
Choline                          PCho                         CDP-choline                         PC 
                                      
                                                                                                                             PEMT 
 
                           EK                        ECT                                             EPT 
Ethanolamine                   PEtn                          CDP-ethanolamine              PE 
                        
 
Figure 1.1: Kennedy pathway for the biosynthesis of phosphatidylcholine (PC) 
and phosphatidylethanolamine (PE). Choline kinase (CKα or CKβ) phosphorylates 
choline to form phosphocholine (PCho). PCho is converted into CDP-choline by 
CTP-phosphocholine cytidylyltransferase (CCT). CDP-choline is condensed into PC 
by CDP-choline phosphoryltransferase (CPT). Ethanolamine kinase (EK) 
phosphorylates ethanolamine to form phosphoethanolamine (PEtn). PEtn is 
converted into CDP-ethanolamine by phosphoethanolamine cytidylyltransferase 
(ECT). CDP-ethanolamine is condensed into PE by ethanolamine 
phosphotransferase (EPT). PE can be converted into PC by phosphoethanolamine 
methyltransferase (PEMT). Figure is adapted from Aoyama et al. (2004). 
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50 and 52 kDa, respectively (Aoyama et al., 2004); whereas, CKβ (NCBI reference 
sequence: NP_005189) is encoded by a separated gene with the calculated molecular 
size of 45 kDa. 
 
The enzyme activity of CK was first described in brewer’s yeast by Wittenberg and 
Kornberg (1953). Due to the difficulty in purifying yeast CK, the understanding of 
CK progressed slowly until the highly homogeneous CK was obtained from rat 
tissues in 1984 (Ishidate et al., 1984, Porter and Kent, 1990, Uchida and Yamashita, 
1990). The cDNA of rat and human CKα1 was first isolated from rat liver and 
human glioblastoma (Hosaka et al., 1992, Uchida and Yamashita, 1992a). Amino 
acid sequence comparison between rat and human CKα1 shows 84.9% identity. 
Later, the second transcript of rat CKα1, termed CKα2 was isolated and 
characterized (Uchida, 1994). CKα2 and CKα1 are differed by an extra stretch of 18 
amino acids on the CKα2 isoenzymes with a discrepancy of 2 kDa. The insertion of 
extra amino acids on the CKα2 significantly increased its substrate affinity for 
choline (Malito et al., 2006). The additional stretch of amino acid was proposed to 
be the important region to facilitate the conformational change of the enzyme upon 
substrate binding (Malito et al., 2006).  
 
Another isoenzyme of CK, named CKβ was first cloned from rat liver and 
characterized by Aoyama et al. (1998). The amino acid sequence of rat CKβ shows 
57-59% identity with the amino acid sequence of rat CKα1 and CKα2. The human 
homolog of rat CKβ was identified later by Yamazaki et al. (1997). The cDNA 
sequence of human chkβ was cloned in a large-scale cDNA sequence project and the 
sequence was deposited in NCBI with GenBank accession number: BC082263, 
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BC101488, BC113521(Strausberg et al., 2002). CKβ consists of 395 amino acids. 
CKβ is less studied as compared to the CKα isoenzyme. CKβ is not as active as CKα. 
Most importantly, CKβ is not involved in tumorigenesis as compared to CKα, which 
is the main factor for most of the studies were focused on CKα isoenzyme (Gallego-
Ortega et al., 2009). CKβ started to attract attention when the association between 
CKβ and muscular dystrophy was reported (Wu et al., 2009). 
 
CK from Caenorhabditis elegans has been extensively studied also. The second 
isoenzyme of C. elegans CK from family A (CKA-2) shows 48% identity with the 
human CKα2. Due to its high similarity in gene sequence and biochemical 
properties to human CKα2, CKA-2 has been used as the model for structure function 
study for better understanding of CK function (Gee and Kent, 2003). 
 
1.3 Structure of choline kinase 
CKs consist of two clusters of highly conserved motif, Brenner’s and CK/EK motif 
(Figure 1.2). Brenner’s motif with consensus sequence of hxHxDhx3N (h refers to 
large hydrophobic residue and x refers to an unknown amino acid residue) is found 
in most of the protein kinases that catalyze the transfer of phosphoryl groups 
(Brenner, 1987), whereas, CK/EK motif (hxhhDhEx4Nx3hDhx2HhxE) is conserved 
among the CK from different organisms (Aoyama et al., 2000). 
 
CKA-2 from C. elegans was the first crystal structure to be solved (Peisach et al., 
2003). The crystal structure of CKA-2 revealed the enzyme as a homodimeric 
protein. The structure of CKA-2 is similar with those eukaryotic protein kinases 
(ePK) and aminoglycoside phosphotransferases (AP) although their amino acid  
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Figure 1.2: Sequence alignment of CK from human, mouse and C. elegans. The 
NCBI accession numbers for human CKs; hCKα1, hCKα2 and hCKβ are 
NP_997634, NP_001268, and NP_005189. The NCBI accession numbers for mouse 
CKs; mCKα and mCKβ are NP_038518 and NP_031718. The NCBI accession 
number for C. elegans; CKA-2 is NP_001024480. Figure is adapted from Malito et 
al. (2006). 
 
Brenner’s  motif CK/EK motif 
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sequences are different. Structural comparison of CKA-2 with the catalytic subunit 
of protein kinase A (PKA) and aminoglycoside 3’-phosphotransferase [APH(3’)-IIIa] 
shows conserved structural cores of a N and C-terminal domains. The conserved 
structure of the N-terminal region consists of five strands of β sheet (first five 
strands) and one helix (second helix), whereas the C-terminal domain consists of 
three helices (third to fifth helices) and four strands of β sheet (ninth to twelfth 
strands). The smaller N-terminal domain is connected to the large C-terminal 
domain by a short linker. The crystal structure of CKA-2 also showed the location of 
Brenner’s and the CK/EK motif at the C-terminal domain. There was no bound 
substrate, so the ATP site was predicted based on the existing structure of highly 
similar proteins ePK and AP. The choline binding site was proposed to be near to 
the ATP binding pocket which was formed by several structurally flexible loops 
(Peisach et al., 2003). 
 
Later, Malito et al. (2006) solved the crystal structure of human CKα2 protein with 
bound ADP and PCho to reveal the molecular details of ATP and the choline 
binding sites on CKα2. The ribbon diagram of the CKα2 crystal structure is shown 
in Figure 1.3. CKα2 was also crystalized as homodimeric form. The structure of 
CKα2 is very similar with the structure of CKA-2. As compared to the CKA-2, a 
small difference is found on the fifth helix of CKα2. However, this region is not part 
of the catalytic region. 
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                              CKα2                                                        CKβ 
 
Figure 1.3: Ribbon diagrams of human CKα2 and CKβ. CKα2 (PDB 3G15) and 
CKβ were bound with the hemicholinium (HC-3) (PDB 3FEG). C and N indicate C 
and N-terminal regions. The dimeric structure shown of CKβ was the suggested 
biological model based on the asymmetric unit of CKβ (Hong et al., 2010). 
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CKα2 overexpressed in E. coli BL21(DE3) was the N-terminal truncation mutant 
without the first 49 amino acids (Malito et al., 2006). The truncated version of the 
CKα2 shows very similar biochemical properties as the full length protein and this 
suggests that the N-terminus of CKα2 is not important for enzyme catalysis. On the 
crystal structure, the first visible residue is on the Pro 85 which indicates that the 
first 30 amino acids on the crystal structure are disordered. In this structure, the 
choline binding pocket is described as a deep hydrophobic groove with a rim of 
negatively charged residues. ATP is bound within a cleft between two domains (the 
N and C-terminal domain) of the enzyme. Residues from both N and C-terminal 
lobes contribute to the formation of large pocket for ATP binding. Upon binding of 
choline, it undergoes conformational changes affecting the N-terminal domain and 
the ATP-binding loop.  
 
Subsequently, Hong et al. (2010) solved the crystal structure of another CK 
isoenzyme, CKβ in complex with the potent CK inhibitor, hemicholinium (HC-3). 
HC-3 molecule was bound onto the choline binding pocket. The structure of CKβ 
exhibited the same bilobal architecture as CKα2 with the major difference being the 
C-terminal lobe (Figure 1.3) (Hong et al., 2010). This difference lowers the 
sensitivity of CKβ towards HC-3 inhibition (Hong et al., 2010). Besides, the N-
terminal truncated (35 amino acids) CKβ was shown as a monomer rather than 
dimer like the CKα2 and CKA-2. The first 35 amino acid might be important for the 
oligomeric formation.  
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Mutagenesis study was performed on the conserved Brenner’s and CK/EK motif 
based on information obtained from the crystal structural of CK and other ePK with 
similar protein structure. Aspartate residue on Brenner’s motif was responsible for 
the removal of the proton charge from the hydroxyl group of ATP (Zheng et al., 
1993). Thus, mutation on the Asp 255 residue of CKA-2 and Asp 306 residues of 
CKα2 caused the total loss of CK activity (Malito et al., 2006, Yuan and Kent, 
2004). On the other hand, mutation on the CK/EK motif also impaired the catalytic 
activity of CK. These residues were shown to coordinate the enzyme co-factor, Mg
2+
 
ion by two carboxyl oxygen atoms. Mutation on Asn 260 and Asp 301 on CK/EK 
motif of CKA-2 resulted in the loss of the enzyme activity (Peisach et al., 2003; 
Yuan and Kent, 2004). However, mutation on the Asn 330 on the CK/EK motif of 
CKα2 did not alter the catalytic activity although the crystal structure of CKα2 
showed a direct contact of this residue with Mg
2+
 ion (Malito et al., 2006). Besides, 
Ser 121 in the ATP loop is also important for the activity of CK. Mutation of this 
residue decreased the catalytic efficiency of the enzyme. Hydroxyl group on this 
position is essential for a full activity of the CKα2 protein. 
 
1.4 CK oligomeric structures 
CK exists as dimer, tetramer or higher oligomer. Homo or hetero-oligomer 
formation of CK isoforms had been reported. According to Aoyama et al. (2002), 
the most active form of CK in mouse is the homo-oligomer of α/α, followed by 
hetero-oligomer of α/β and the least active CK is homo-oligomer of β/β. The mRNA 
abundance of CKα isoform was the highest in testis, while the expression of CKβ 
isoform was relatively high in the heart and liver. In liver tissue, hetero-oligomer 
contributed 60% of the total activity, while the homo-oligomer contributed 20% 
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each to the remaining activity. In contrast, the enzyme obtained from heart tissue 
showed 70% of activity from homo-oligomer of β/β, 25% from hetero-oligomer of 
α/β, and <5% was contributed by the homo-oligomer of α/α (Aoyama et al., 2002). 
These observations indicate that the expression, distribution and the combination of 
the CK oligomer were tissue type-dependent.  
 
The dimeric structure of CKα2 protein is stabilized by the dimer interface formed at 
the second α-helix (Glu 175 ̶ Arg 190) of each monomer (Malito et al., 2006). For 
CKA-2, another dimer interface is identified at the first helix (Pro 50  ̶Leu 64) and 
the S-shaped loop [formed by the fourth (Ala 167 ̶ His 174) and fifth (Leu 194 ̶ Thr 
208) helices] (Peisach et al., 2003). The extra dimer interface on CKA-2 is absent 
from the CKα2 protein as the structure at this region is disordered (Malito et al., 
2006). In mouse CK, the important regions for oligomer formation were also 
identified (Liao et al., 2006). The amino acids between first (Pro 73 ̶ Arg 85) and 
ninth helices (Gln 424 ̶ Lys 430) as well as single amino acid on seventh helix, Asp 
320 are critical for oligomer formation of CKα. The region between first (Arg 35 ̶ 
Arg 62) and tenth helices (Gln 379 ̶ Lys 385) is important for oligomer formation of 
CKβ (Liao et al., 2006).  
 
1.5 CK subcellular location 
In early studies, CK had been reported as a cytosolic protein. The CK activity was 
detected in the cytosol fraction of the cells (Uchida and Yamashita, 1990; Aoyama 
et al., 2002). In addition, Miyake and Parsons (2011) also showed CKα as a 
cytoplasmic protein when overexpressed in breast cancer cell line. CKα was 
translocated from cytoplasm to the membrane of the cell when co-expressed with its 
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interacting partner, the epidermal growth factor receptor (EGFR) (Miyake and 
Parsons, 2011). Besides, there was also a report on nucleus translocation of CKα at 
the mitotic phase of the cell cycle (Gruber et al., 2012). These observations provide 
the evidences for CKα translocation into different cell compartments. However, no 
information is available for the subcellular location of CKβ.  
 
1.6 Biochemical properties of CK 
Extensive biochemical characterizations of CK from rat, S. cerevisiae and C. 
elegans had been performed in the earlier studies (Gee and Kent, 2003, Ishidate et 
al., 1984, Kim et al., 1998, Porter and Kent, 1990, Uchida and Yamashita, 1990, 
Ishidate et al., 1985). The details were summarized in Table 1.1 (Aoyama et al., 
2004). Among rat CK, CKα2 possessed the highest specific activity, followed by 
CKα1 and the least active form of CK is CKβ (Ishidate et al., 1984; Ishidate et al., 
1985; Porter and Kent, 1990; Uchida and Yamashita, 1990). As compared to rat CK, 
the similar characteristic was reported for human CK (Hong et al., 2010). Yeast CK 
(S. cerevisiae) was almost as active as the rat CKα2 with lower affinity towards 
choline (Kim et al., 1998). In contrast, C. elegans CK was less active than the yeast 
CK. However, its affinity toward choline was higher than the yeast CK (Gee and 
Kent, 2003).  
 
All the purified CKs possess EK activity (Aoyama et al., 2004; Hong et al., 2010). 
Therefore, the nomenclature of CK becomes choline/ethanolamine kinase in the 
early nineties. The subsequent discovery of Drosophila EK established the existence 
of a separate gene (ek) encoding an ethanolamine specific kinase (Uchida, 1997). In 
human, the cDNA of the ek1 gene was isolated and characterized by Lykidis et al. 
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Table 1.1 The catalytic activity of CK from rat, S. cerevisiae and C. elegans. 
The table is adapted from Aoyama et al. (2004). 
 
Source Oligomeric 
form 
S.A(mmol
/min/mg) 
Km 
Choline 
(μM) 
Km 
ATP 
(mM) 
Corresponding 
protein 
Rat kidneya,b dimer 3.3 100 1.5 CKβ 
Rat liverc tetramer 143 13 0.04 CKα2 
Rat braind dimer 40 14 1.0 CKα1 
S. cerevisiaee 
(Recombinant) 
dimer 128 270 0.09 CKI 
C. elegansf 
(Recombinant) 
Dimer 
(oligomer) 
43 
24 
1.6 mM 
13 mM 
2.4 
0.72 
CKA-2 
CKB-2 
 
a
 Ishidate et al. (1984) 
b
 Ishidate et al. (1985) 
c
Porter and Kent (1990) 
d
 Uchida and Yamashita (1990) 
e
 Kim et al. (1998) 
f
 Gee and Kent (2003) 
 
S.A: specific activity. 
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(2001). It possessed high EK activity with negligible CK activity. In general, CK 
prefers choline rather than ethanolamine as substrate. The affinity of CK for choline 
is higher than ethanolamine (Porter and Kent, 1990). Gallego-Ortega et al. (2009) 
reported that both human CKα and CKβ isoforms showed higher affinity toward 
choline rather than ethanolamine. However, human CKβ showed a higher 
ethanolamine kinase activity than CK activity in the cells (Gallego-Ortega et al., 
2009). The overexpression of CKα in human derived cell line increased the 
production of both PCho and PEtn. However, CKβ overexpression increased PEtn 
production, but not PCho (Gallego-Ortega et al., 2009), which showed that CKβ 
catalyzed the phosphorylation of ethanolamine rather than choline when both 
substrates are present in the cell.  
 
In terms of the substrate affinity, CKα purified from bacterial expression system 
possesses a higher affinity for both choline and ethanolamine than the CKβ (See Too, 
2006). CKα overexpressed from human derived cell line (crude cell lysate) also gave 
similar results (Gallego-Ortega et al., 2009). However, Hong et al. (2010) showed a 
contradicting result. Their purified CKβ from bacterial expression system had a 
higher substrate affinity for choline than CKα although the catalytic efficiency of 
CKα remained higher than the CKβ isoenzyme. 
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1.7 The roles of choline kinase 
1.7.1 Cell proliferation 
CK is involved in cell proliferation. The product of CK, PCho was shown to induce 
mitogenesis. In human primary mammary epithelial cells (HMEC) and mouse 
embryonic fibroblast cells (NIH 3T3), PCho production was increased by growth 
factor, insulin and hydrocortisone treatments, which were the effectors for normal 
cell proliferation (Ramirez de Molina et al., 2004, Kiss and Chung, 1996). The 
treatment also increased the DNA synthesis of HMEC cells and promotes G1 to S 
phase transition of the cell cycle (Ramirez de Molina et al., 2004). CK 
overexpression was found to alter the expression of 31 genes and promote cell 
proliferation (Ramirez de Molina et al., 2008). The expression of transforming 
growth factor beta (TGF-β), one of the important proteins in G1 cell cycle arrest was 
down-regulated by the overexpression of CK (Ramirez de Molina et al., 2008). The 
role of CK in down regulating cell arrest was further confirmed by specific CK 
inhibitor, MN58b. MN58b was shown to reverse the TGF-β mediated transcriptional 
activation which was activated by CK overexpression (Ramirez de Molina et al., 
2008). In addition, Yamashita and Hosaka (1997) showed that CK mRNA and 
protein levels were elevated during the exponential phase of tumor cell growth but 
decreased in the stationary phase. This leads to the accumulation of PC which is the 
end product of CK. The accumulation of PC resulted from an increased level of CK 
protein at the enterance of S phase was also found to be essential for cell division 
(Lykidis and Jackowski, 2001).  
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1.7.2 Tumorigenesis 
CK is overexpressed in both tumorous tissue and tumor derived cell lines (Ramirez 
de Molina et al., 2002a, Ramirez de Molina et al., 2002b, Ramirez de Molina et al., 
2007, Hernando et al., 2009). The overexpression of CK was detected at both 
mRNA and protein levels (Eliyahu et al., 2007). Furthermore, the levels of the 
choline metabolites were also elevated in cancerous cells (Katz-Brull et al., 2002, 
Iorio et al., 2005, Eliyahu et al., 2007). These observations raise the question of 
whether CK acts as an oncogene or as a byproduct of the physiological alteration 
associated with oncogene expression.  
 
Earlier study showed that overexpression of CK was the consequence of 
tumorigenic transformation. Bhakoo et al. (1996) showed the elevation of PCho in 
ras oncogene transformed cell. The activity of CK was up-regulated by ras protein 
through the direct effectors of Ral-GDS and phosphoinositide 3-kinase (PI3K), two 
of the important mediators for tumorigenesis (Ramirez de Molina et al., 2002a). 
Treatment with the PI3K inhibitor (PI-103) was shown to suppress the expression 
level of CK and in turn decrease the level of PCho production and total choline 
metabolites in the cells (Al-Saffar et al., 2010). In addition, the activity of 
serine/threonine kinase (AKT), one of the protein kinase in PI3K pathway was also 
regulated by CK (Chua et al., 2009). Besides, the breakdown product of PC, 
phosphatidic acid was found as the key activator for the PI3K pathway (Yalcin et al., 
2010). Knockdown of the phospholipase D, the enzyme to hydrolyze PC was shown 
to attenuate the activation of AKT (Toschi et al., 2009). 
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Oncogenic property of CK in tumor transformation was reported by Ramirez de 
Molina et al. (2005). Overexpression of CK induced oncogenic transformation of 
human embryo epithelial kidney fibroblasts (HEK293) and Madin-Darby canine 
kidney cells (MDCK). Co-expression of CK with RhoA from GTPases family 
further potentiates anchorage independent growth and tumorigenesis. This suggested 
that CK plays role in Rho-mediated tumor transformation. The role of CK in cell 
transformation was further confirmed by the specific CK inhibitor, MN58b, which 
inhibited the CK mediated tumorigenesis (Ramirez de Molina et al., 2005).  
 
Later, Gallego-Ortega et al. (2009) showed that the CKα isoform was oncogenic and 
able to induce cell transformation, but not CKβ isoform. The overexpression of CKβ 
did not induce tumor growth. In addition, the study also showed the CKα but not 
CKβ mRNA was elevated in a panel of mammary cancer cell line as compared to 
the non-tumorogenic mammary cell lines (Gallego-Ortega et al., 2009). 
 
CKα is an important enzyme in cancer cell survival. CKα knockdown in cervical 
cancer cell line (HeLa) using small interfering RNA (siRNA) resulted in cell death 
(Glunde et al., 2005, Falcon et al., 2013). However, the inhibition of CKα activity 
with specific inhibitor, MN58b is not sufficient to induce cell death. This result 
indicates that the non-catalytic role of CKα is important for the cancer cell survival 
(Falcon et al., 2013). Cells with single CKβ or double CKα/CKβ knockdown have 
no aberrant phenotype compared to the single knockdown of CKα (Gruber et al., 
2012). In this case, the balance of the CKα and CKβ isoforms also important for 
cancer cell survival and simultaneous knockdown of CKβ reduced or abolished the 
cell-killing effect of single CKα knockdown (Gruber et al., 2012). 
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1.7.3 Differential role of CKα and CKβ 
CKα and CKβ knockout mice generated a different phenotype. Early embryonic 
lethality was observed on CKα knockout mice (Wu et al., 2008) while CKβ 
knockout mice developed muscular dystrophy (Sher et al., 2006). Thus, CKα plays 
important role in early development of mouse embryo while CKβ is involved in the 
later part of mouse development. Heterozygous CKα knockout mice (ckα+/-) have a 
normal early embryonic development and the biosynthesis of PC was unaffected 
although the PC synthesis was decreased by 30% (Wu et al., 2008). No significant 
compensation was found from CKβ in homo and heterozygous CKα knockout mice 
because the mRNA and protein levels of CKβ were not increased in both of the CKα 
knockout mice (Wu et al., 2008). The evidence supported that CKα and CKβ have 
different roles in maintaining the PC homeostasis.  
 
Sher et al. (2006) reported that CKβ knockout mice developed hindlimbs muscular 
dystrophy and neonatal forelimb bone deformity. Total CK activity was generally 
decreased in all tissues, however muscle dystrophy was only observed in skeletal 
muscle of hindlimbs (Sher et al., 2006). CKβ was involved in PC metabolism of 
hindlimb muscle, while CKα was responsible for PC synthesis in forelimb muscle as 
muscular dystrophy did not develop in forelimbs due to CKα abundance and stable 
PC homeostasis (Wu et al., 2010). CKα was not overexpressed in the CKβ knockout 
mice to compensate for the loss of CKβ activity (Wu et al., 2009). 
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Mitochondria abnormalities were observed on the skeletal muscle of CKβ knockout 
mice whereby mitochondria were absent on the center of muscle fibers and large 
mitochondria was found at the peripheral fiber (Mitsuhashi et al., 2011a, Wu et al., 
2009). The PC level was low in the isolated mitochondria. The activity of the 
respiratory chain enzyme (complex I-IV) and the ATP production of the defected 
mitochondria in CKβ knockout mice also decreased. In addition, the molecular 
markers of mitophagy were found in the defected mitochondria suggested that the 
loss of ckβ gene resulted in mitochondria dysfunction and led to the development of 
muscular dystrophy (Mitsuhashi et al., 2011a).  
 
In human, heterozygous mutation of chkβ was detected in 15 patients with 
congenital muscular dystrophy from Japan, Turkey and Britain (Mitsuhashi et al., 
2011b). CK activity was not detected in the muscle tissue of the patients and the PC 
content of the frozen biopsied muscle tissues was lower than normal individual. A 
total of 11 mutations were identified and these mutations mostly truncated the 
protein or eliminated the conserved region of CKβ protein (Mitsuhashi et al., 2011b). 
Besides muscular dystrophy, patients with chkβ gene mutation also have severe 
mental retardation (Mitsuhashi et al., 2011b). Previously, the decreased CKβ 
expression has been linked with narcolepsy, a sleep disorder (Miyagawa et al., 
2008). The findings supported the involvement of CKβ in the maintenance of 
normal brain function in humans.  
 
Gutierrez Rios et al. (2012) also reported the chkβ gene mutation in an American 
patient with congenital muscle dystrophy. The mutation also truncated the protein by 
introducing a stop codon at Gln 292. Giant mitochondria containing densely packed 
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and whorled cristae were observed in the tissue biopsy. The authors concluded that 
CKβ was involved in mitochondria-associated membrane phospholipid metabolism 
(Gutierrez Rios et al., 2012). They also postulated that CKβ gene defect could 
consequently affect the production of active human muscle type carnitine 
palmitoyltransferase I (M-CPTI) protein, a key lipid transport enzyme in the outer 
membrane of mitochondrial. The transcription of chkβ and cpt1β genes were 
bicistronic (Yamazaki et al., 2000). In consequence, the mitochondria dysfunction 
might also be due to the defect of cpt1β gene expression which affect the activity of 
mitochondrial respiratory chain. 
 
1.8 Regulation of choline kinase 
1.8.1 Transcriptional level 
Several studies on the promoter regions have shed light on the transcription 
regulation of CK genes by transcription factors. Aoyama et al. (2007) reported an 
up-regulation of CKα expression in mouse liver after treatment with carbon 
tetrachloride (CCl4). The overexpression of CK was contributed by the binding of c-
jun transcription factor to an AP-1 element (at   ̶ 866 bp upstream of translational 
start site) upon treatment with CCl4 (Aoyama et al., 2007).  
 
In human, the putative promoter region upstream of ckα gene ( ̶ 2.3 kb region 
upstream of translational start site) was isolated by Glunde et al. (2008). Their study 
showed that the expression of CKα was regulated by hypoxic condition. Eight 
hypoxia responsive elements (HREs) sites were predicted by promoter sequence 
analysis. The responsive elements composed of two non-overlapping regions which 
up-regulated ( ̶ 1068/ ̶ 851) and down-regulated (  ̶ 670/+1) the CKα expression 
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during hypoxia (Glunde et al., 2008). Highly repressive element was found at the 
position  ̶ 225/ ̶ 222 bp upstream of translational start site (Bansal et al., 2012). The 
binding of hypoxia-inducible factor (HIF-1α) on the respective HRE sites was 
shown to suppress the mRNA expression of CKα (Glunde et al., 2008; Bansal et al., 
2012).  
 
Recently, Yee (2012) reported the isolation of promoter region of human ckβ gene   
( ̶ 2 kb region upstream of translational start site). GATA and Ets were identified as 
the important transcription factors that suppressed the expression of CKβ expression 
(Yee, 2012).  
 
1.8.2 Translational level 
To date, translational regulation of CK had not been reported. The translational 
regulation of CTP-phosphocholine cytidyltransferase (CCT), a second enzyme in 
CDP-choline pathway had been postulated in X-box-binding protein (XBP-I(S)) 
transducted fibroblasts (Sriburi et al., 2007). The expression of the XBP-I(S) was 
shown to increase the assembled (80S) ribosomes which enhanced the protein 
synthesis of CCT. However, the detailed mechanism of XBP-I(S) in enhancing the 
translation of CCT needs further investigation.  
 
1.8.3 Post-translational level 
Post-translational regulation of CK by phosphorylation was first described in yeast 
CK. Yeast CK is phosphorylated by protein kinase A (PKA) and protein kinase C 
(PKC) (Kim and Carman, 1999, Yu et al., 2002, Choi et al., 2005). Phosphorylation 
of yeast CK with PKA and PKC increased the catalytic activity by 1.9 and 1.6 folds, 
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respectively (Kim and Carman, 1999, Choi et al., 2005). Furthermore, 
phosphorylation of yeast CK was shown to increase the production of PCho and PC. 
Ser 30 and Ser 85 residues were identified as the PKA phosphorylation sites (Yu et 
al., 2002), whereas Ser 25 and Ser 30 residues were identified as the PKC 
phosphorylation sites (Choi et al., 2005). PKA and PKC were found to 
phosphorylate yeast CK at the same residue of Ser 30 (Choi et al., 2005).  
 
In human, regulation of CKα by phosphorylation had been reported by Miyake and 
Parsons (2011). This proto-oncogene tyrosine protein kinase Src (c-Src) dependent 
phosphorylation occurred at Tyr 197 and Tyr 333. Phosphorylation of CKα was 
important for its interaction with EGFR complex. The phosphorylation level of CKα 
was increased by c-Src co-expression. The phosphorylation increased the catalytic 
activity of CKα by 2.5 folds (Miyake and Parsons, 2011). In addition, the subcellular 
location of CKα is also affected by phosphorylation. Co-expression of c-Src and 
EGFR translocated the CKα protein from cytosol to the cell membrane (Miyake and 
Parsons, 2011).  
 
CTP-phosphocholine cytidylyltransferase (CCT), the second enzyme in CDP-
choline pathway is also regulated by phosphorylation (Dennis et al., 2011). The 
phosphorylated form of CCT is inactive and retained in cytosol, while the 
unphosphorylated form of CCT is active and being translocated to the cell 
membrane for PC biosynthesis (Hatch et al., 1992). The isoforms of CCTα and 
CCTβ possess a divergent N-terminal and C-terminal phosphorylation region. 
Generally, the binding affinity of CCTβ towards anion membrane was weaker than 
the CCTα isoforms. However, after phosphorylation, CCTβ showed a higher binding 
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affinity to the anion membrane than the phosphorylated CCTα isoforms (Dennis et 
al., 2011).  
 
1.9 Phosphorylation 
About one third of the human proteins are reported as phosphoproteins (Cohen, 
2000). The modification occurs rapidly and less energy is required since it does not 
involve re-synthesis or degradation of the existing protein. Furthermore, the process 
of phosphorylation is reversible (Fischer and Krebs, 1955). Protein kinase is 
responsible for protein phosphorylation by transferring the phosphate (PO4
3-
) group 
from ATP, while protein phosphatase removes the phosphate group from the protein 
substrate. In eukaryotes, the hydroxyl groups (OH) of serine, threonine and tyrosine 
amino acid side chains are the common targets of protein phosphorylation (Manning 
et al., 2002).  
 
The process of phosphorylation was first described by Burnett and Kennedy (1954). 
They showed that a liver enzyme catalyzed the phosphorylation of casein. A year 
later, Fischer and Krebs (1955) discovered a process known as reversible 
phosphorylation of an enzyme involved in glycogenolysis. They won the Nobel 
Prize in medicine in 1992 by showing the phosphorylation of glycogen 
phosphorylase. The process involved the phosphorylation of phosphorylase b 
(unphosphorylated form) into phosphorylase a (phosphorylated form) in the 
presence of metal ion and ATP. Later, the key enzyme called protein kinase 
involved in phosphate transfer was discovered (Fischer and Krebs, 1955). Extensive 
investigation was then focused on protein phosphorylation after Linn et al. (1969) 
suggested that phosphorylation played a key role in the regulation of metabolic 
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pathway. This led to the discovery of important protein kinases in different 
metabolic pathways. 
 
Phosphates are negatively charged, thus the addition of a phosphate group onto a 
protein will certainly change its characteristic (Kitchen et al., 2008). These changes 
had been reported to regulate the function of enzyme, cellular movement, protein-
protein interaction and protein stability (Johnson and Barford, 1993, Nishi et al., 
2011). Tight regulation of protein phosphorylation is important and phosphorylation 
is generally regulated by the balance between the activity of protein kinases and 
phosphatases.  
 
1.10 Protein kinase A 
PKA holoenzyme is a heterotetramer protein composed of two regulatory (R) 
subunits and two catalytic (C) subunits (Corbin et al., 1973, Corbin and Keely, 
1977). Two classes of PKA holoenzymes have been identified; type I and type II 
with the difference in the R subunit with RI for type I and RII for type II. Both R 
and C subunits exist as multiple isoforms; RIα, RIβ, RIIα, RIIβ, Cα, Cβ, and Cγ. 
Type I PKA is mostly found in the cytosol of the cell, while the type II is anchored 
in a specific compartment. Generally, the type I holoenzyme has a higher affinity 
towards cAMP than the type II holoenzyme (Tasken and Aandahl, 2004). RI subunit 
is expressed predominantly in brain and nervous system, while the RII subunit is 
generally detected in heart, liver and fat tissues (Cummings et al., 1996). Cα subunit 
is expressed ubiquitously, while the other isoforms are detected in specific tissues. 
For example the Cγ is mostly found in testis (Beebe et al., 1990). 
 
24 
 
PKA holoenzyme is inactive. There are two cAMP binding sites on each R subunit 
of PKA, known as A and B sites. Only B site is exposed and available for binding of 
the cAMP. When the B site is occupied, it enhances the binding of cAMP to the A 
site by an intramolecular steric change. Bindings of four cAMP molecules on both R 
subunits cause a conformational change and the holoenzyme is dissociated into 
dimer R subunit and monomer of C subunits (Kopperud et al., 2002). The 
dissociated C subunits are active and able to phosphorylate the nearby substrate. 
Figure 1.4 shows the schematic diagram of the PKA activation. PKA phosphorylates 
the serine and threonine residues in specific consensus sequences of RRXS/T, 
AKXS/T, and KKXS/T, X represents any residue (Shabb, 2001, Songyang et al., 
1994). 
 
1.10.1 Regulation of Protein kinase A 
PKA is regulated by the cAMP-signaling pathway. The pathway is triggered 
extracellularly via binding of a specific ligand to the G protein-coupled receptor 
(GPCRs). The ligands are small molecules such as catecholamines, lipids, 
neurotransmitters or a large protein for example hormones. Upon binding of the 
ligand on the receptor, GPCRs will undergo conformational change and activate the 
heterotrimeric G protein. This leads to the dissociation of α subunit of G protein 
from β and γ subunits and activates the adenylyl cyclases. The activated adenylyl 
cyclases are responsible to increase the intracellular level of cAMP by converting 
ATP into cAMP (Taylor et al., 1990, Pidoux and Tasken, 2010). The cAMP-
signaling pathway is shown in Figure 1.5. Conversely, phosphodiesterases (PDEs) 
are responsible to control the local pool of adenylyl cyclase-generated cAMP by  
 
